GCV Asia Congress 2018
Skip Content

12 March 2018

Humacyte fixes $75m series C

Humacyte, an Access Industries-backed developer of tissue-based biological repair technology, has now raised $290m in financing in total.

Author: Robert Lavine, News Editor

Humacyte, a US-headquartered developer of tissue-based medical technology that counts conglomerate Access Industries as an investor, completed a $75m series C round on Friday.